

Q2 2023 *results*



- We delivered another solid quarter of growth and are excited by the momentum of our R&D pipeline, with a strong flow of positive readouts and regulatory achievements that match our best-in-class ambitions. •

Paul Hudson

Chief Executive Officer, Sanofi

Company sales and business EPS*

€9,965m

+3.3% (-1.5%)

Q2 2023
company sales **



Anais Brafine,
Nanobody Research Platform, Belgium

€1.74

+8.1% (+0.6%)

Q2 2023
business EPS **

* Earnings per share

** Growth rates are expressed at constant exchange rates (CER).
Growth rates in parentheses are expressed on a reported basis.

Sales by global business unit




€4,403m

Specialty Care



€3,114m

General Medicines



Antibody



€1,223m

Vaccines



€1,225m

Consumer Healthcare

Sales by geography

US

€3,919m

Europe

€2,458m



Keegan O'Keefe, Research & Biomarkers,
Waltham, Massachusetts

Rest of
the World

€3,588m

Key R&D milestones



Respiratory
syncytial
virus (RSV)

US FDA approves
our RSV prevention
for newborns
and infants



Chronic obstructive
pulmonary disease
(COPD)

Positive
phase 3 data
for one of our
innovative
biologics



Atopic
dermatitis

Positive topline
phase 2b data
of novel
investigational
anti-OX40-ligand
monoclonal
antibody



Multiple
sclerosis

Positive
phase 2b data
for our novel
anti-CD40L
antibody

For further information on Q2 2023 results and definitions of financial indicators, please refer to the press release issued on July 28, 2023 at: www.sanofi.com/en/investors

sanofi



@Sanofi



@Sanofi



@Sanofi



@Sanofi